Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06126809 · ClinicalTrials.gov registry record · NA
Causal Role of the Aperiodic Signal for Working Memory
A NA study of Executive Dysfunction, sponsored by Florida State University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06126809: Recruiting NA study of Executive Dysfunction, sponsored by Florida State University.
NCT06126809 is a NA study of Executive Dysfunction that is actively recruiting participants, run by Florida State University. The registered enrollment target is 30 participants, below the 136-participant average among 17 other Executive Dysfunction trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06126809, a NA study of Executive Dysfunction, is actively recruiting participants, sponsored by Florida State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Working memory (WM) is the ability to hold relevant information in mind in the absence of sensory input. The capacity for WM is a foundation for cognitive control and higher cognitive function more broadly. Previous research demonstrated that during the delay period of WM tasks, oscillatory electrical activity in the prefrontal cortex in the theta-frequency band (4-8 Hz) increased in amplitude. However, other groups found that the slope of the aperiodic signal in the brain was positively correlated with individual differences in WM capacity. Since low-frequency power and a steeper slope of the aperiodic signal are confounded in many analyses, it is not clear whether the slope of the aperiodic signal or the amplitude of low-frequency oscillations underlie WM capacity. With many studies investigating the causal role of theta oscillations in WM, the purpose of this project is to investigate the role of the aperiodic signal in WM performance.
Primary Outcome
The number of remembered items, often referred to as working memory capacity, is calculated as the number of items to be remembered multiplied by the number of items successfully remembered divided by the number of total trials. The range of values is 0 to 7 where a larger number denotes a greater number of items that were remembered.
Conditions Studied
Interventions
- DEVICE Steep-tRAS
- DEVICE Flat-tRAS
- DEVICE Sham-tRAS
Study Locations (1)
Florida
- Florida State University - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06126809 shows while recruiting
NCT06126809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 136-participant average among 17 other Executive Dysfunction trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Executive Dysfunction appearing as the primary indexed condition, and to 3 interventions - of which Steep-tRAS is the first listed.
NCT06126809 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06126809 about?
NCT06126809 is a clinical study titled "Causal Role of the Aperiodic Signal for Working Memory". Working memory (WM) is the ability to hold relevant information in mind in the absence of sensory input. The capacity for WM is a foundation for cognitive control and higher cognitive function more broadly. Previous research demonstrated that during the delay period of WM tasks, oscillatory electric...
What is the current status of trial NCT06126809?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-03-25. Estimated completion is 2026-12.
What conditions does trial NCT06126809 study?
This clinical trial studies the following conditions: Executive Dysfunction.
What interventions are being tested in trial NCT06126809?
The interventions under investigation include: Steep-tRAS (DEVICE), Flat-tRAS (DEVICE), Sham-tRAS (DEVICE).
Who is sponsoring clinical trial NCT06126809?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06126809 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Executive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06126809's enrollment target sits among peer trials
30 13th of 17 higher than 4 of 17 other Executive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Executive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
HOPS Study: A Conceptual Replication
RECRUITING · NA
-
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia
RECRUITING · NA
-
Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy
RECRUITING · NA
-
Transcranial Direct Current Stimulation in Children With Autism
RECRUITING · NA
-
Randomized Controlled Trial of a Behavioral Training App
RECRUITING · NA
-
Engage for Late-Life Depression and Comorbid Executive Dysfunction
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI